## Abstract The objective of this study was to evaluate the safety, tolerability, and preliminary efficacy of intravenous glutathione in Parkinson's disease (PD) patients. This was a randomized, placeboโcontrolled, doubleโblind, pilot trial in subjects with PD whose motor symptoms were not adequate
A double-blind evaluation of ciladopa in Parkinson's disease
โ Scribed by Dr. William J. Weiner; Stewart A. Factor; Juan Sanchez-Ramos; Joseph Berger
- Publisher
- John Wiley and Sons
- Year
- 1987
- Tongue
- English
- Weight
- 416 KB
- Volume
- 2
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract As many as 40% of patients with Parkinson's disease (PD) use some form of complementary medicine during the course of their illness, and many try acupuncture. One nonblinded study of the effects of acupuncture in PD suggested that it might be helpful for some aspects of PD. We performed
## Abstract We studied the effects of noninvasive transcranial electrical stimulation on the motor and psychological symptoms of early Parkinson's disease. Twentyโthree subjects were treated with 10 days of placebo versus active treatment and then followed for 14 weeks. Baseline off medication Unif
## Abstract The objective of this study was to evaluate the efficacy and safety of pramipexole extended release (ER) administered once daily in early Parkinson's disease (PD). Pramipexole immediate release (IR) administered three times daily (TID) is an efficacious and generally wellโtolerated trea
## Abstract This study examined the efficacy and safety of the partial dopamine agonist, pardoprunox (SLV308), in the treatment of patients with early Parkinson's disease (PD). Patients were randomized to receive pardoprunox (n = 69) or placebo (n = 70). Pardoprunox was titrated to each patient's o
## Abstract We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a doubleโblind, placeboโcontrolled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Vi